InspireMD Inc (NYSEMKT:NSPR) Stock Price Balloons On Device Data


InspireMD Inc (NYSEMKT:NSPR), whose MicroNet technology is used in its products for coronary, carotid (CGuard™), neurovascular, and peripheral artery procedures, more than doubled in value Tuesday after the release of follow-up data from its Paradigm-101 trial of the CGuard Embolic Prevention System (EPS).

The stock rocketed 134.27% to close at $3.35 with 9.17 million shares changing hands. At its high of the day of $4.39, the stock had gained over 200% from its Monday close.

Technically, the runaway moves in the stock after October 7 show that the stock may now never close the gap between $0.08 and $1.40, and may have entered a long term uptrend.

InspireMD Inc (NYSEMKT:NSPR) reports excellent follow-up data on CGuard EPS

In a presentation titled “Twelve-month Safety and Efficacy of CGuard™ Micronet-Covered Embolic Prevention Stent System: Routine Use to Perform Carotid Revascularization in Symptomatic and Increased Stroke Risk Asymptomatic Patients: The PARADIGM All-Comer Prospective Academic Study,” the company said blood vessel narrowing was reduced from 83±9% to only 6.7±5%, the CGuard EPS device and procedure success were each 99.1%, and that there were zero device-related adverse events at 12 months.

“These data further reinforce the strong safety and efficacy profiles reported in previous trials of the CGuard EPS, and validate the system as an important option for endovascular management of patients with carotid artery disease,” said Prof. Piotr Musialek, MD, DPhil, FESC, from the Jagiellonian University Department of Cardiac & Vascular Diseases, in Krakow, Poland.

Prof. Piotr Musialek presented the data at the Transcatheter Cardiovascular Therapeutics 2016 scientific symposium in Washington, D.C.

InspireMD Inc (NYSEMKT:NSPR) CGuard EPS – How it works

Patients with symptomatic carotid stenosis are typically treated by placement of a stent inside the blood vessel in order to re-open the carotid artery and improve blood flow to the brain.

InspireMD’s CGuard EPS uses the company’s patented MicroNet technology to provide the revascularization benefits of a stent with a mesh “safety net” that secures the plaque against the blood vessel’s arterial wall and thereby prevents plaque and other debris from flowing through the stent’s scaffold.


Leave A Reply